Literature DB >> 8647803

Phosphatidylinositol 3-kinase is an early intermediate in the G beta gamma-mediated mitogen-activated protein kinase signaling pathway.

B E Hawes1, L M Luttrell, T van Biesen, R J Lefkowitz.   

Abstract

The beta gamma-subunit of Gi mediates mitogen-activated protein (MAP) kinase activation through a signaling pathway involving Shc tyrosine phosphorylation, subsequent formation of a multiprotein complex including Shc, Grb2, and Sos, and sequential activation of Ras, Raf, and MEK. The mechanism by which G beta gamma mediates tyrosine phosphorylation of Shc, however, is unclear. This study assesses the role of phosphatidylinositol 3-kinase (PI-3K) in G beta gamma-mediated MAP kinase activation. We show that Gi-coupled receptor- and G beta gamma-stimulated MAP kinase activation is attenuated by the PI-3K inhibitors wortmannin and LY294002 or by over expression of a dominant negative mutant of the p85 subunit of PI-3K. Wortmannin and LY294002 also inhibit Gi-coupled receptor-stimulated Ras activation. The PI-3K inhibitors do not affect MAP kinase activation stimulated by over-expression of Sos, a constitutively active mutant of Ras, or a constitutively active mutant of MEK. These results demonstrate that PI-3K activity is required in the G beta gamma-mediated MAP kinase signaling pathway at a point upstream of Sos and Ras activation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8647803     DOI: 10.1074/jbc.271.21.12133

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  66 in total

1.  S338 phosphorylation of Raf-1 is independent of phosphatidylinositol 3-kinase and Pak3.

Authors:  A Chiloeches; C S Mason; R Marais
Journal:  Mol Cell Biol       Date:  2001-04       Impact factor: 4.272

2.  Bradykinin B(2) receptor-mediated mitogen-activated protein kinase activation in COS-7 cells requires dual signaling via both protein kinase C pathway and epidermal growth factor receptor transactivation.

Authors:  A Adomeit; A Graness; S Gross; K Seedorf; R Wetzker; C Liebmann
Journal:  Mol Cell Biol       Date:  1999-08       Impact factor: 4.272

Review 3.  Chemokine signalling: pivoting around multiple phosphoinositide 3-kinases.

Authors:  Adam P Curnock; Marisa K Logan; Stephen G Ward
Journal:  Immunology       Date:  2002-02       Impact factor: 7.397

Review 4.  Diversity of G protein-coupled receptor signaling pathways to ERK/MAP kinase.

Authors:  Mariana M Belcheva; Carmine J Coscia
Journal:  Neurosignals       Date:  2002 Jan-Feb

5.  Schwann cell survival mediated by the signaling phospholipid lysophosphatidic acid.

Authors:  J A Weiner; J Chun
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

6.  Cannabinoid CB1 receptors transactivate multiple receptor tyrosine kinases and regulate serine/threonine kinases to activate ERK in neuronal cells.

Authors:  George D Dalton; Allyn C Howlett
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

7.  The second galanin receptor GalR2 plays a key role in neurite outgrowth from adult sensory neurons.

Authors:  Sally-Ann Mahoney; Richard Hosking; Sarah Farrant; Fiona E Holmes; Arie S Jacoby; John Shine; Tiina P Iismaa; Malcolm K Scott; Ralf Schmidt; David Wynick
Journal:  J Neurosci       Date:  2003-01-15       Impact factor: 6.167

8.  Activated human hydroxy-carboxylic acid receptor-3 signals to MAP kinase cascades via the PLC-dependent PKC and MMP-mediated EGFR pathways.

Authors:  Q Zhou; G Li; X Y Deng; X B He; L J Chen; C Wu; Y Shi; K P Wu; L J Mei; J X Lu; N M Zhou
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

9.  Mechanisms of endothelin-1-induced MAP kinase activation in adrenal glomerulosa cells.

Authors:  Bukhtiar H Shah; Albert J Baukal; Hung-Dar Chen; Ali B Shah; Kevin J Catt
Journal:  J Steroid Biochem Mol Biol       Date:  2006-12       Impact factor: 4.292

Review 10.  Regulation of organic cation transport.

Authors:  Giuliano Ciarimboli; Eberhard Schlatter
Journal:  Pflugers Arch       Date:  2004-11-16       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.